CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
PF-06823859 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05037409
NCT05037409Phase 1Completed
CompareCT.gov

A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETICS FOLLOWING SINGLE INTRAVENOUS DOSE OF PF-06823859 IN JAPANESE HEALTHY PARTICIPANTS

Pfizer·interventional·Posted Sep 8, 2021·Updated Dec 15, 2023

In Brief

A Phase 1 clinical trial evaluating PF-06823859 and Placebo for Healthy. Completed, enrolled 13 participants across 1 site.

Detailed Summary

Purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK) of PF-06823859 following a single intravenous dose of PF-06823859 300 and 900 mg in Japanese healthy adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedSep 8, 2021
Enrollment StartSep 28, 2021
Primary CompletionMar 27, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.8 years ago

Interventions

PF-06823859drug

low dose or high dose intravenous infusion

Placebodrug

Intravenous infusion